akers biosciences, inc

November, 2014

Forward Looking StatementsAll statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Akers Biosciences, Inc. (ABI or the Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov.

Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business.

The Company disclaims any intent or obligation to update these forward-looking statements.

COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR

2

Introduction

• Bringing diagnostics to the point-of-care

• Multiple core products with blockbuster potential

• Faster, better diagnostics which take costs out of the healthcare system


3


Products Selling NOW

4

• ABI sells the only FDA cleared rapid test to detect heparin allergies; competes with expensive, slow turn-around laboratory tests

• 25 million patients in US and EU receive heparin annually

• 4 million tests performed annually in laboratories in US which could be replaced with PIFA


STAT Point-of-Care

5

Only combined rapid test for Total, HDL and LDL cholesterol


6


Research & Discovery

Clinical Development

Commercial Development

Launch & Market Entry

Pipeline products

Dengue Fever

Troponin I

Chlamydia

Malaria

Diabetic Ketoacidosis

COPD

Lung Cancer

Asthma

7

Developing the world’s first rapid diagnostic assays for Lung CancerAsthma & COPD through breath

• LUNG CANCER: > 1.6 million people diagnosed each year

• ASTHMA: Up to 15% of a country’s population may have Asthma

• COPD: 1 billion smokers at risk for COPD


8

Improving how diabetics manage Ketoacidosis

• Type 1, and some Type 2, diabetics are at risk for developing ketoacidosis (blood acid build-up)

• 3 million type 1 diabetics in US

• Reduces healthcare costs by decreasing the need for hospital visits and expensive lab testing


9

Milestones


• Enhance sales and marketing capabilities

• Create more international alliances: Konica Minolta, Joint Venture in China

• Expand US and International distribution of PIFA PF4 products

• Launch international distribution of Breath Ketone “Check” and expand Tri-Cholesterol “Check”

• Establish US distribution channels for Tri-Cholesterol “Check”, METRON and VIVO

10

• New healthcare environment demands cost-containment

• Multiple products with blockbuster potential, some already selling

• Substantial new product pipeline with mass market potential

• Company underpinned by multiple valuable technology platforms

Summary


11

Appendix

Profit and Loss


Nine Months Fiscal YearEnded Sep 30 Ending Dec 31

2014 2013 2012

Revenue $2,980,389 $3,577,851 $1,564,101

Gross Profit 2,072,513 1,664,007 556,150

Administrative Expenses 2,497,485 1,524,626 1,493,707

Sales & Marketing Expenses 966,357 684,720 638,732

Research & Development Expenses 686,376 1,006,800 900,380

Operating Loss (2,271,634) (1,526,773) (2,725,228)

Net Loss (2,214,915) (1,526,773) (2,557,820)

13

Balance Sheet Overview


As of

Sep 30, 2014 Dec 31, 2013

Total Assets 16,782,653 6,075,622

Total Liabilities 1,054,944 1,953,388

Total Equity 15,727,709 4,122,234

14

Capitalization Structure


Sep 30, 2014Shares

Common Shares 4,954,837

Directors & Officers Options – Exercise Price of $5.50 115,000

Key Employee Options – Exercise Price of $3.98 60,000

Warrants – Exercise Price of $71.76 1,989

Total – Fully Diluted 5,131,826

15

Experienced Board

Raymond F. Akers, Jr. Ph.D.Founder, Executive Chairman of the Board (Director)• 30+ years in medical diagnostics; founded ABI in 1989• Invented most of ABI’s products and technologies; numerous patents• Ph.D. in Neurochemistry, Northwestern University


Gavin E.D. MoranNon-Executive Director• Extensive experience in trading, finance and marketing• Trading roles at Shell International, Trafigura Ltd, and since April 2010, beneficial shareholder at Sono International Ltd

Brandon T. KnoxNon-Executive Director• Experience in corporate finance and financial management• Currently wealth advisor at Raymond James

Thomas J. KnoxNon-Executive Vice Chairman• Expertise in health care and finance• Former CEO of United Healthcare of Pennsylvania; Former Chairman of the Board and Chief Executive Officer of Fidelity Insurance

Group, Inc.• Currently Chief Executive Officer of Knox Consulting Group, Chairman of ORB Automotive Corporation, Ltd

16


Product SummaryCommercial DevelopmentClinical Development Launch & Market Entry

Asthma

COPD*

*Chronic Obstructive Pulmonary Disorder

Diabetic Ketoacidosis

Commercial DevelopmentClinical Development Launch & Market Entry

Hep B / Hep C

HIV 1 + 2

Lung Cancer

Syphilis / Gonorrhea

Dengue Fever

17

akers biosciences, inc

Investor Relations

aker lse

forwardlooking statements

copd copyright2014 nasdaq

akr products

pifa copyright2014 nasdaq

akr stat point

lung cancer asthma copd

company products